Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial

(2021) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Comparative Risk of Serious Infections with Tumor Necrosis Factor-α Antagonists vs. Vedolizumab in Patients with Inflammatory Bowel Diseases

(2021) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Providing the Best Care for Patients With Crohn’s Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

(2021) Edith Y. Ho et al.   GASTROENTEROLOGY

AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

(2021) Siddharth Singh et al.   GASTROENTEROLOGY

OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study

(2020) S Vermeire et al.   Journal of Crohns & Colitis

Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment

(2020) Glen S. Hazlewood et al.   PLoS One

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment

(2020) Vince B. C. Biemans et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: medical therapy for fibrostenosing Crohn’s disease

(2020) Cathy Lu et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

(2020) William J Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease

(2020) Julien Kirchgesner et al.   Clinical Gastroenterology and Hepatology

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis

(2019) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

(2019) Nicholas A Kennedy et al.   Lancet Gastroenterology & Hepatology

Positioning Therapies in the Management of Crohn’s Disease

(2019) Nghia H. Nguyen et al.   Clinical Gastroenterology and Hepatology

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses

(2019) Kenji Watanabe et al.   JOURNAL OF GASTROENTEROLOGY

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease

(2018) S. Singh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-Analysis

(2018) Matthew J. Lee et al.   Clinical Gastroenterology and Hepatology

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review for Development of a Core Outcome Set

(2018) Christopher Ma et al.   Clinical Gastroenterology and Hepatology

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease

(2018) Heike Schmitt et al.   GUT

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

(2017) Yoram Bouhnik et al.   GUT

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

(2017) Stephan R. Vavricka et al.   INFLAMMATORY BOWEL DISEASES

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes

(2016) Christopher Ma et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial

(2016) Takayuki Matsumoto et al.   Journal of Crohns & Colitis

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

(2015) Reena Khanna et al.   LANCET

Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease

(2014) Silvio Danese et al.   CURRENT DRUG TARGETS

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis

(2014) Uri Kopylov et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

(2011) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET